Matt Miksic
Stock Analyst at Barclays
(3.85)
# 698
Out of 4,479 analysts
142
Total ratings
58.96%
Success rate
4.84%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $130 → $125 | $106.27 | +17.62% | 5 | May 31, 2024 | |
| PODD Insulet | Maintains: Equal-Weight | $213 → $200 | $197.19 | +1.43% | 5 | May 13, 2024 | |
| GMED Globus Medical | Maintains: Overweight | $83 → $85 | $68.05 | +24.91% | 7 | May 9, 2024 | |
| EW Edwards Lifesciences | Maintains: Overweight | $100 → $101 | $91.23 | +10.71% | 9 | May 7, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $39 → $55 | $39.15 | +40.49% | 3 | May 6, 2024 | |
| SYK Stryker | Maintains: Overweight | $372 → $376 | $334.30 | +12.47% | 8 | May 2, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $70 → $78 | $76.55 | +1.89% | 7 | Apr 26, 2024 | |
| ABT Abbott Laboratories | Maintains: Overweight | $141 → $140 | $103.20 | +35.66% | 17 | Apr 22, 2024 | |
| INMD InMode | Maintains: Overweight | $34 → $33 | $17.41 | +89.55% | 8 | Apr 12, 2024 | |
| ZIMV ZimVie | Maintains: Underweight | $13 → $16 | $18.14 | -11.80% | 7 | Mar 5, 2024 | |
| LIVN LivaNova | Maintains: Equal-Weight | $57 → $61 | $52.89 | +15.33% | 5 | Feb 27, 2024 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $17 → $18 | $14.66 | +22.78% | 4 | Feb 26, 2024 | |
| BAX Baxter International | Maintains: Overweight | $52 → $54 | $32.85 | +64.38% | 9 | Feb 12, 2024 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $385 → $430 | $438.81 | -2.01% | 4 | Jan 25, 2024 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $158 → $162 | $146.03 | +10.94% | 9 | Oct 12, 2023 | |
| DXCM DexCom | Maintains: Equal-Weight | $115 → $138 | $112.49 | +22.68% | 4 | Jul 31, 2023 | |
| MDT Medtronic | Upgrades: Overweight | $89 → $104 | $77.37 | +34.42% | 8 | Apr 24, 2023 | |
| ALC Alcon | Assumes: Outperform | $96 | $88.79 | +8.12% | 6 | May 13, 2022 | |
| HSIC Henry Schein | Assumes: Outperform | $100 | $65.60 | +52.44% | 3 | May 13, 2022 | |
| ALGN Align Technology | Maintains: Outperform | $722 → $418 | $239.74 | +74.36% | 3 | May 4, 2022 | |
| SHC Sotera Health Company | Maintains: Outperform | $31 → $28 | $11.63 | +140.76% | 2 | Mar 2, 2022 | |
| XRAY DENTSPLY SIRONA | Maintains: Outperform | $68 → $67 | $24.44 | +174.14% | 1 | Mar 1, 2022 | |
| RBOT Vicarious Surgical | Initiates: Outperform | $480 | $6.56 | +7,217.07% | 1 | Jan 7, 2022 | |
| IART Integra LifeSciences Holdings | Maintains: Outperform | n/a | $29.19 | - | 5 | Nov 3, 2021 | |
| ORGO Organogenesis Holdings | Maintains: Outperform | n/a | $2.66 | - | 1 | Aug 10, 2021 | |
| MDXG MiMedx Group | Initiates: Sell | n/a | $6.78 | - | 1 | Dec 12, 2016 |
Zimmer Biomet Holdings
May 31, 2024
Maintains: Underweight
Price Target: $130 → $125
Current: $106.27
Upside: +17.62%
Insulet
May 13, 2024
Maintains: Equal-Weight
Price Target: $213 → $200
Current: $197.19
Upside: +1.43%
Globus Medical
May 9, 2024
Maintains: Overweight
Price Target: $83 → $85
Current: $68.05
Upside: +24.91%
Edwards Lifesciences
May 7, 2024
Maintains: Overweight
Price Target: $100 → $101
Current: $91.23
Upside: +10.71%
Tandem Diabetes Care
May 6, 2024
Maintains: Overweight
Price Target: $39 → $55
Current: $39.15
Upside: +40.49%
Stryker
May 2, 2024
Maintains: Overweight
Price Target: $372 → $376
Current: $334.30
Upside: +12.47%
Boston Scientific
Apr 26, 2024
Maintains: Overweight
Price Target: $70 → $78
Current: $76.55
Upside: +1.89%
Abbott Laboratories
Apr 22, 2024
Maintains: Overweight
Price Target: $141 → $140
Current: $103.20
Upside: +35.66%
InMode
Apr 12, 2024
Maintains: Overweight
Price Target: $34 → $33
Current: $17.41
Upside: +89.55%
ZimVie
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $18.14
Upside: -11.80%
LivaNova
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $57 → $61
Current: $52.89
Upside: +15.33%
Bausch + Lomb
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $14.66
Upside: +22.78%
Baxter International
Feb 12, 2024
Maintains: Overweight
Price Target: $52 → $54
Current: $32.85
Upside: +64.38%
Intuitive Surgical
Jan 25, 2024
Maintains: Overweight
Price Target: $385 → $430
Current: $438.81
Upside: -2.01%
Johnson & Johnson
Oct 12, 2023
Maintains: Equal-Weight
Price Target: $158 → $162
Current: $146.03
Upside: +10.94%
DexCom
Jul 31, 2023
Maintains: Equal-Weight
Price Target: $115 → $138
Current: $112.49
Upside: +22.68%
Medtronic
Apr 24, 2023
Upgrades: Overweight
Price Target: $89 → $104
Current: $77.37
Upside: +34.42%
Alcon
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $88.79
Upside: +8.12%
Henry Schein
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $65.60
Upside: +52.44%
Align Technology
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $239.74
Upside: +74.36%
Sotera Health Company
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $11.63
Upside: +140.76%
DENTSPLY SIRONA
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $24.44
Upside: +174.14%
Vicarious Surgical
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $6.56
Upside: +7,217.07%
Integra LifeSciences Holdings
Nov 3, 2021
Maintains: Outperform
Price Target: n/a
Current: $29.19
Upside: -
Organogenesis Holdings
Aug 10, 2021
Maintains: Outperform
Price Target: n/a
Current: $2.66
Upside: -
MiMedx Group
Dec 12, 2016
Initiates: Sell
Price Target: n/a
Current: $6.78
Upside: -